News
The company is testing its lead asset, a CAR T/NK-cell therapy, in a Phase I trial in patients with B-cell malignancies.
NEW YORK – Kelonia Therapeutics this week said it has started treating patients with relapsed and refractory multiple myeloma in a Phase I trial of its in vivo CAR T-cell therapy KLN-1010.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback